AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs

VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lUIAoz
via IFTTT